News >

Nivolumab/Ipilimumab Combo Active in Sarcoma

Jason Harris
Published: Wednesday, Jun 21, 2017

Sandra P. D’Angelo, MD

Sandra P. D’Angelo, MD

Dual checkpoint inhibition with nivolumab (Opdivo) plus ipilimumab (Yervoy) induced an objective response rate (ORR) of 16% (90% CI, 7-29) in patients with heavily treated, unselected, metastatic sarcoma, according to findings from the phase II ALLIANCE A091401 trial presented at the 2017 ASCO Annual Meeting.

In the monotherapy arm, 86% of discontinuations were due to progression compared with 74% in the combination arm. Fifteen percent of patients in the combination arm discontinued due to AEs compared with 2% on monotherapy.
D’Angelo SP, Mahoney MR, Van Tine BA, et al. A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401). J Clin Oncol. 35, 2017 (suppl; abstr 11007).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x